APA (7th ed.) Citation

Garassino, M. C., Gadgeel, S., Novello, S., Halmos, B., Felip, E., Speranza, G., . . . Paz-Ares, L. (2023). Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC. JTO clinical and research reports, 4(1), 100431. https://doi.org/10.1016/j.jtocrr.2022.100431

Chicago Style (17th ed.) Citation

Garassino, Marina C., et al. "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC." JTO Clinical and Research Reports 4, no. 1 (2023): 100431. https://doi.org/10.1016/j.jtocrr.2022.100431.

MLA (9th ed.) Citation

Garassino, Marina C., et al. "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC." JTO Clinical and Research Reports, vol. 4, no. 1, 2023, p. 100431, https://doi.org/10.1016/j.jtocrr.2022.100431.